GREY:ATBPF - Post by User
Post by
Duster340on Feb 27, 2023 1:34pm
190 Views
Post# 35307563
Just a reminder
Just a reminderfrom feb/15th
"As we prepare for the Phase II bunionectomy trial, we're increasingly excited about the potential of otenaproxesul's new formulation," noted Dan Legault, Antibe's CEO. "Recent animal data have confirmed both its potential for effective pain management at dramatically lower doses and a rapid onset profile ideally suited for acute pain. To de-risk the translation of this data to human doses, we've planned a confirmatory study in healthy volunteers upon release of the new drug tablets. We look forward to delivering Phase II top-line data in the next 12 months."
The Company also announced that its founder, Dr. John L. Wallace, has decided to retire from the Board of Directors. Dr. Wallace will remain a corporate Vice Chair, enabling the Company to continue to benefit from his wisdom and expertise.